3rd Edition of International Heart Congress
June 05-07,2025 | Hybrid Event
Valvular Atrial Fibrillation
Valvular Atrial Fibrillation (VAF) is a specific subtype of atrial fibrillation characterized by the presence of significant heart valve disease. In individuals with VAF, irregular and often rapid heartbeats occur due to abnormal electrical signals in the atria, the upper chambers of the heart. The presence of valvular heart disease, such as mitral stenosis or a mechanical heart valve, increases the risk of developing VAF. Managing VAF poses unique challenges, as treatment strategies need to consider both the atrial fibrillation and the underlying valvular pathology. Healthcare professionals typically tailor their approach based on factors like the severity of the valve disease, overall health status, and individual patient considerations. Close monitoring and a collaborative, multidisciplinary approach are essential in addressing the complexities of Valvular Atrial Fibrillation.
Shuping Zhong
University of Southern California, United States
Yong Xiao Wang
Albany Medical Center, United States
Yochai Birnbaum
Baylor College of Medicine, United States
Federico Benetti
Benetti Foundation, Argentina
Thomas Bernd Dschietzig
Relaxera GmbH & Co. KG, Germany
Mekhman N Mamedov
National Research Center for Preventive Medicine, Russian Federation
Narendra Kumar
HeartbeatsZ Academy, United KingdomSubmit your abstract Today
Title : Surgical fetal stem cells implantation in heart failure patients long term results at 14 years
Federico Benetti, Benetti Foundation, Argentina
Title : Exploring new biomarkers of cardiomyopathy
Shuping Zhong, University of Southern California, United States
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany
Title : Cancer and cardiovascular diseases: Common pathogenesis mechanisms and risk factors
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Pulse field ablation for atrial fibrillation complications: What do we know yet
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : Lipoprotein (a): The hidden cardiovascular risk
Syed Raza, Awali Hospital, Bahrain